Oncology

Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

December 14, 2007
Stephen Jones
Stephen Jones

STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.

Download this interview

Add podcast to iTunes

Similar Interviews

  • Non-Anthracyline Regimen May Be O.K. for Patients with Early Breast Cancer taking Trastuzumab (Herceptin)

    • Dennis Slamon, UCLA School of Medicine, Los Angeles It may be reasonable to replace the anthracycline component of adjuvant chemotherapy with

  • Audio Journal of Oncology 14.1, February 2006

    • Reporting from: - San Antonio Breast Cancer Symposium 2005 In this edition: The targeted drug trastuzumab may be used in place of anthracyclines

  • For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival

    • [caption id="attachment_984" align="alignnone" width="120" caption="Charles Coombes"][/caption]Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival

    Post a comment